Pulmonary Embolism Risk Reduced With New Treatment
Patients with intermediate-high-risk lung blood clots saw fewer grave outcomes with a specialized catheter procedure.
Updated on Sept. 21, 2026 in Heart Disease
Live Poll
Should doctors adopt new catheter-based treatments for common pulmonary embolism cases?
A new clinical trial found that catheter-directed thrombolysis significantly lowered the risk of life-threatening events in patients with intermediate-high-risk acute pulmonary embolism. The findings, presented at the European Society of Cardiology Congress, suggest a more effective intervention for preventing collapse or death.
Why it matters
Pulmonary embolism carries high mortality rates, making the identification of treatments that can stabilize patients rapidly a clinical priority. This trial provides evidence that adding targeted thrombolysis to standard anticoagulation may offer a superior pathway for patient outcomes.
In the 558-patient PRAGUE-26 trial, catheter-directed thrombolysis plus anticoagulation was compared to anticoagulation alone, with primary outcomes measured at 7 days. The treatment arm demonstrated a significant reduction in grave outcomes, with a number needed to treat of 17 to prevent one event.
The players
European Society of Cardiology
A professional society focused on heart disease research, clinical guidelines, and education.
PRAGUE-26 trial
A randomized clinical study evaluating treatment interventions for pulmonary embolism.
The details
The procedure uses a catheter to deliver thrombolytic medication, which is designed to actively dissolve the blood clot directly in the lung arteries. By combining this local delivery with systemic anticoagulation, the approach seeks to rapidly restore blood flow and reduce pressure on the heart. While effective, the trial noted that two patients treated with thrombolysis experienced intracranial hemorrhage, a serious complication.
Timeline
7 days was the primary outcome measurement period.
September 2026 marked the trial presentation at the ESC Congress.
2027 is the expected year for the release of new pulmonary embolism guidelines.
Health Landscape
This study sits at the center of ongoing clinical discussions at the European Society of Cardiology Congress regarding optimal management for high-risk patients. It provides updated data that will likely shape the next generation of international treatment protocols.
If you or a loved one are diagnosed with an intermediate-high-risk pulmonary embolism, these findings highlight the importance of discussing all available procedural options with a cardiologist. Always confirm with your physician whether specialized interventions like thrombolysis are appropriate based on your specific bleeding risk profile.
The takeaway
This trial demonstrates that targeted catheter-based treatment can significantly improve outcomes for specific pulmonary embolism patients compared to medication alone. Patients should track any symptoms of cardiorespiratory distress and ask their physician about the latest evidence-based protocols.
What happens next
New guidelines for the management of pulmonary embolism are currently expected to be released in 2027.
Further reading
For more background on managing clotting conditions, visit our Heart Disease section.
Source note: This article includes information reported by Healio.
Live Poll
Should doctors adopt new catheter-based treatments for common pulmonary embolism cases?
